Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

7 results about "Suicide gene" patented technology

A suicide gene, in genetics, will cause a cell to kill itself through apoptosis. Activation of these genes can be due to many processes, but the main cellular "switch" to induce apoptosis is the p53 protein. Stimulation or introduction (through gene therapy) of suicide genes is a potential way of treating cancer or other proliferative diseases. Suicide genes form the basis of a strategy for making cancer cells more vulnerable, more sensitive to chemotherapy. The approach has been to attach parts of genes expressed in cancer cells to other genes for enzymes not found in mammals that can convert a harmless substance into one that is toxic to the tumor. Most suicide genes mediate this sensitivity by coding for viral or bacterial enzymes that convert an inactive drug into toxic antimetabolites that inhibit the synthesis of nucleic acid. Suicide genes must be introduced into the cells in ways that ensure their uptake and expression by as many cancer cells as possible, while limiting their expression by normal cells. Suicide gene therapy for cancer requires the vector to have the capacity to discriminate between target and non target cells, between the cancer cells and normal cells.

HLA class I MHC cell excision

This invention provides compositions and methods for reducing the immunogenicity of cells for transplantation, including cell-based immunotherapy. [Solution] A vector encoding β2-microglobulin (B2M) modified RNA, along with a targeting moiety and other signaling and / or suicide genes, enables the efficient generation of engineered CAR T regulatory cells or other therapeutic cells derived from any source. The present invention provides, for example, vectors encoding β2-microglobulin (B2M) modified RNA and chimeric antigen receptors (CARs).
Owner:AZTHERAPIES INC

Armored chimeric antigen receptor t cells

The present application relates to sequences for expression in engineered chimeric antigen receptor (CAR) T cells for targeting IL13Ra2. In some embodiments, the sequences include a humanized VHH binder specific to IL13Ra2, an intracellular signaling domain, armoring elements to support cell persistence and functionality, or any combination thereof. Also disclosed herein are T cells that include a suicide gene for controlled cell elimination, and therapeutic uses thereof.
Owner:CHIMERIS UK LTD +1

Her2-based suicide switch

The present application relates to a suicide gene system and its use as part of immunotherapy. In some embodiments, the suicide gene system is expressed in a CAR T-cell, optionally along with armoring proteins. The present application also discloses uses of the suicide gene system, such as in cell tracking, immune regulation, rapid elimination of CAR T-cells, and as part of a therapeutic treatment.
Owner:CHIMERIS UK LTD +1

Safe and controllable chimeric antigen receptor loaded with suicide gene, macrophages expressing same and application thereof

The application uses gene editing technology to design and optimize a safe and controllable chimeric antigen receptor loaded with a suicide gene, and a macrophage expressing the same, the chimeric antigen receptor comprising a single-chain variable region targeting carcinoembryonic antigen (CEA), a hinge region, a transmembrane region, and an intracellular signaling region. The application has the following advantages: the chimeric antigen receptor-Hoxb8 macrophage CAR-Hoxb8-M has high infiltration, enhanced phagocytosis and antigen presentation capacity, and is expected to become a new strategy for the immunotherapy of solid tumor cells. The constructed stem progenitor cells proliferate rapidly, can be obtained in large quantities in a short time, and can be frozen for long-term preservation. The induction of macrophages is short, simple and convenient, the macrophages efficiently express CAR, are stable and uniform, small molecule compounds regulate the fate of progenitor cells and macrophages, are safe and controllable, and have an anti-colorectal cancer treatment effect. The CAR-Hoxb8-M combined with an immune checkpoint inhibitor can further inhibit tumor growth and improve survival rate.
Owner:NANJING UNIV

Engineered immune cells expressing a car and a plurality of protein expression blockers and uses thereof

The present invention provides one or more expression vectors encoding one or more of an anti-CD7 chimeric antigen receptor (CAR), an anti-CD7 protein expression blocker, a kill gene or a suicide gene, and an anti-CD3 protein expression blocker. Also provided are immune cells comprising the one or more expression vectors. Also provided are methods of producing such one or more expression vectors or immune cells. Also provided are methods of using such one or more expression vectors or immune cells for treating cancer while reducing symptoms of Graft-versus-host disease (GvHD).
Owner:IASO BIOTHERAPEUTICS USA LTD

Gene therapeutic vector for KSHV-associated diseases

PCT designated stageWO2026055462A1VectorsPeptide/protein ingredientsDiseaseMalignancy
Disclosed are compositions and methods for the treatment of KSHV-infected malignancies through administering an AAV gene therapy vector. The AAV vector encodes two copies of the TR sequence, a gene promoter and a suicide gene. The gene therapy vector leads to tumor cell apoptosis and further reactivation of KSHV transactivator to further activate therapeutic genes.
Owner:RGT UNIV OF CALIFORNIA

Secreted RNA therapeutics for nuclear delivery

Disclosed herein is a system that addresses the current challenges described by combining three existing technologies and an improved nuclear RNA delivery system to generate a first-in-class cellular therapy that can secrete a cancer specific suicide gene for the treatment of several cancers. The system generally involves a first poly nucleotide encoding retroviral elements that preferentially binds and facilitates formation and secretion of vesicles carrying its own RNA messenger operably linked to a first expression control sequence; a second polynucleotide encoding an RNA therapeutic having a nuclear retention sequence that is flanked by packaging signals for the retroviral elements operably linked to a second expression control sequence; and a third polynucleotide encoding a membrane fusion protein operably linked to a third expression control sequence.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC